These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 19650870)

  • 1. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.
    Bauer PO; Nukina N
    J Neurochem; 2009 Sep; 110(6):1737-65. PubMed ID: 19650870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurodegenerative polyglutamine expansion diseases: physiopathology and therapeutic strategies].
    Ravache M; Abou-Sleymane G; Trottier Y
    Pathol Biol (Paris); 2010 Oct; 58(5):357-66. PubMed ID: 20299163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular biology of polyglutamine diseases].
    Owecki M; Kozubski W
    Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
    Hannan AJ
    Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanisms of neurodegeneration in polyglutamine diseases].
    Tsuji S
    Rinsho Shinkeigaku; 2003 Nov; 43(11):901-2. PubMed ID: 15152498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset.
    Pulst SM; Santos N; Wang D; Yang H; Huynh D; Velazquez L; Figueroa KP
    Brain; 2005 Oct; 128(Pt 10):2297-303. PubMed ID: 16000334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1).
    Orr HT
    Neurobiol Dis; 2000 Jun; 7(3):129-34. PubMed ID: 10860780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic strategies for the polyglutamine diseases].
    Nagai Y; Popiel HA; Fujikake N; Toda T
    Brain Nerve; 2007 Apr; 59(4):393-404. PubMed ID: 17447526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAG repeat disorder models and human neuropathology: similarities and differences.
    Yamada M; Sato T; Tsuji S; Takahashi H
    Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research progress in roles of microRNA in polyglutamine diseases].
    Shi YT; Jiang H; Tang BS
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):406-9. PubMed ID: 20677146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pathogenic agent in Drosophila models of 'polyglutamine' diseases.
    McLeod CJ; O'Keefe LV; Richards RI
    Hum Mol Genet; 2005 Apr; 14(8):1041-8. PubMed ID: 15757976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
    Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
    Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways.
    Gunawardena S; Goldstein LS
    Arch Neurol; 2005 Jan; 62(1):46-51. PubMed ID: 15642849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic mutation and human disorders: the spinocerebellar ataxias (review).
    Costa Lima MA; Pimentel MM
    Int J Mol Med; 2004 Feb; 13(2):299-302. PubMed ID: 14719138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allele-selective suppression of mutant genes in polyglutamine diseases.
    Liu CR; Cheng TH
    J Neurogenet; 2015; 29(2-3):41-9. PubMed ID: 26174158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trinucleotide repeats and neurodegenerative disease.
    Everett CM; Wood NW
    Brain; 2004 Nov; 127(Pt 11):2385-405. PubMed ID: 15329351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The advances in research on phosphorylation of polyglutamine disease].
    Zhou YF; Jiang H; Tang JG; Tang BS
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polyglutamine diseases: a pathologic view].
    Yamada M
    Rinsho Shinkeigaku; 2003 Nov; 43(11):903-5. PubMed ID: 15152499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanded polyglutamine stretches lead to aberrant transcriptional regulation in polyglutamine diseases.
    Shimohata T; Onodera O; Tsuji S
    Hum Cell; 2001 Mar; 14(1):17-25. PubMed ID: 11436350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyglutamine expansion causes neurodegeneration by altering the neuronal differentiation program.
    Abou-Sleymane G; Chalmel F; Helmlinger D; Lardenois A; Thibault C; Weber C; Mérienne K; Mandel JL; Poch O; Devys D; Trottier Y
    Hum Mol Genet; 2006 Mar; 15(5):691-703. PubMed ID: 16434483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.